345 related articles for article (PubMed ID: 30444176)
1. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease.
Baumann A; Nebel A; Granert O; Giehl K; Wolff S; Schmidt W; Baasch C; Schmidt G; Witt K; Deuschl G; Hartwigsen G; Zeuner KE; van Eimeren T
Neurorehabil Neural Repair; 2018 Dec; 32(12):1055-1066. PubMed ID: 30444176
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
[TBL] [Abstract][Full Text] [Related]
3. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.
Sale P; Castiglioni D; De Pandis MF; Torti M; Dall'armi V; Radicati FG; Stocchi F
Eur J Phys Rehabil Med; 2015 Oct; 51(5):569-74. PubMed ID: 26138088
[TBL] [Abstract][Full Text] [Related]
4. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
[TBL] [Abstract][Full Text] [Related]
5. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
[TBL] [Abstract][Full Text] [Related]
6. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis.
Yuan F; Guo X; Wei X; Xie F; Zheng J; Huang Y; Huang Z; Chang Z; Li H; Guo Y; Chen J; Guo J; Tang B; Deng B; Wang Q
Eur J Neurol; 2020 Oct; 27(10):1957-1970. PubMed ID: 32539227
[TBL] [Abstract][Full Text] [Related]
7. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
[TBL] [Abstract][Full Text] [Related]
8. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
[TBL] [Abstract][Full Text] [Related]
9. [The progress in the rehabilitation of dysarthria in Parkinson disease using LSVT (Lee Silverman Voice Treatment)].
Kamińska I; Zebryk-Stopa A; Pruszewicz A; Dziubalska-Kołaczyk K; Połczyńska-Fiszer M; Pietrala D; Przedpelska-Ober E
Otolaryngol Pol; 2007; 61(5):713-8. PubMed ID: 18552005
[TBL] [Abstract][Full Text] [Related]
10. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: a case study.
Sapir S; Spielman J; Ramig LO; Hinds SL; Countryman S; Fox C; Story B
Am J Speech Lang Pathol; 2003 Nov; 12(4):387-99. PubMed ID: 14658991
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
Trials; 2020 May; 21(1):436. PubMed ID: 32460885
[TBL] [Abstract][Full Text] [Related]
12. Prosodic Improvement in Persons with Parkinson Disease Receiving SPEAK OUT!® Voice Therapy.
Boutsen F; Park E; Dvorak J; Cid C
Folia Phoniatr Logop; 2018; 70(2):51-58. PubMed ID: 29996139
[TBL] [Abstract][Full Text] [Related]
13. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease.
Herd CP; Tomlinson CL; Deane KH; Brady MC; Smith CH; Sackley CM; Clarke CE
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002814. PubMed ID: 22895931
[TBL] [Abstract][Full Text] [Related]
14. Hypokinetic Dysarthria in Parkinson's Disease: A Narrative Review.
Atalar MS; Oguz O; Genc G
Sisli Etfal Hastan Tip Bul; 2023; 57(2):163-170. PubMed ID: 37899809
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease.
Tripoliti E; Strong L; Hickey F; Foltynie T; Zrinzo L; Candelario J; Hariz M; Limousin P
Mov Disord; 2011 Nov; 26(13):2434-6. PubMed ID: 21953693
[TBL] [Abstract][Full Text] [Related]
16. Impact of the LSVT on vowel articulation and coarticulation in Parkinson's disease.
Sauvageau VM; Roy JP; Langlois M; Macoir J
Clin Linguist Phon; 2015 Jun; 29(6):424-40. PubMed ID: 25688915
[TBL] [Abstract][Full Text] [Related]
17. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease.
Deane KH; Whurr R; Playford ED; Ben-Shlomo Y; Clarke CE
Cochrane Database Syst Rev; 2001; (2):CD002814. PubMed ID: 11406045
[TBL] [Abstract][Full Text] [Related]
18. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
[TBL] [Abstract][Full Text] [Related]
19. Pathomechanisms and compensatory efforts related to Parkinsonian speech.
Arnold C; Gehrig J; Gispert S; Seifried C; Kell CA
Neuroimage Clin; 2014; 4():82-97. PubMed ID: 24319656
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of intensive voice treatment (LSVT LOUD
Boliek CA; Fox CM
Int J Speech Lang Pathol; 2017 Dec; 19(6):601-615. PubMed ID: 27705010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
